https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/BRKR/bruker-nmr-systems-upgrade-uc-berkeley BiopharmaWatch en 2026-09-21T11:00:00.000Z Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley https://www.biopharmawatch.com/news/NAIA/naia-launch-247-mind-mentor-felix-global-partnership BiopharmaWatch en 2026-09-21T11:00:00.000Z naia Relief Inc. Announces Launch of naia 24/7 Mind Mentor Through Strategic Partnership with Felix Global https://www.biopharmawatch.com/news/ALKS/alkermes-phase-1b-results-alks-7290-adhd BiopharmaWatch en 2026-09-21T11:00:00.000Z Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-isssi-2026-genetic-diversity-ap-sa02 BiopharmaWatch en 2026-09-21T11:00:00.000Z Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates https://www.biopharmawatch.com/news/SCNI/scinai-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-21T11:00:00.000Z Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/INSM/fda-priority-review-insmed-arikayce-mac-lung-disease BiopharmaWatch en 2026-09-21T11:00:00.000Z FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 https://www.biopharmawatch.com/news/PGEN/precigen-fda-platform-technology-designation-adenoverse BiopharmaWatch en 2026-09-21T11:00:00.000Z Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-alzheimers-agitation-survey-results BiopharmaWatch en 2026-09-21T11:00:00.000Z Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day https://www.biopharmawatch.com/news/SEER/seer-announces-cfo-transition BiopharmaWatch en 2026-09-21T11:00:00.000Z Seer Announces CFO Transition https://www.biopharmawatch.com/news/MRK/merck-keytruda-qlex-approval-japan BiopharmaWatch en 2026-09-21T10:45:00.000Z Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan https://www.biopharmawatch.com/news/QAI/qscreen-ai-debt-settlement-directors-officers BiopharmaWatch en 2026-09-21T10:14:00.000Z QScreen AI Announces $681,000 Debt Settlement with Directors and Officers https://www.biopharmawatch.com/news/AVTR/avantor-appoints-new-cfo-todd-garner BiopharmaWatch en 2026-09-21T10:05:00.000Z Avantor appoints new Chief Financial Officer https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-21 BiopharmaWatch en 2026-09-21T07:15:28.129Z Biotech Catalysts to Watch: Key Developments Through 2026 https://www.biopharmawatch.com/news/C43/gi-genius-study-improves-adenoma-detection BiopharmaWatch en 2026-09-21T05:07:00.000Z Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice https://www.biopharmawatch.com/news/TLX/telix-itm-merger-radiopharmaceuticals BiopharmaWatch en 2026-09-21T00:55:00.000Z Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse https://www.biopharmawatch.com/news/INCY/specialised-therapeutics-expands-partnership-with-incyte BiopharmaWatch en 2026-09-20T20:00:00.000Z Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia https://www.biopharmawatch.com/news/ASTS/ast-spacemobile-class-action-lawsuit BiopharmaWatch en 2026-09-20T14:00:00.000Z INVESTOR ALERT: AST SpaceMobile, Inc. (NASDAQ: ASTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit and Should Contact Kessler Topaz Meltzer & Check, LLP https://www.biopharmawatch.com/news/ORBS/eightco-holdings-nasdaq-orbs-meldt-totale-bezittingen-van-ongeveer-usd BiopharmaWatch en 2026-09-20T12:29:00.000Z Eightco Holdings (NASDAQ: ORBS) meldt totale bezittingen van ongeveer USD 380 miljoen, waaronder belangen in OpenAI en Beast Industries, meer dan 16.000 ETH en bijna 302 miljoen WLD-tokens https://www.biopharmawatch.com/news/CUE/cue-biopharma-positive-results-cue-221-phase-2-study BiopharmaWatch en 2026-09-20T10:00:00.000Z Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria https://www.biopharmawatch.com/news/CAH/class-action-lawsuit-cardinal-health-expenses BiopharmaWatch en 2026-09-19T22:32:00.000Z Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Cardinal Health 414, LLC, for Alleged Failure to Reimburse Employees' Business Expenses